Mouri Pharma

Mouri Pharma is a clinical-stage biotechnology company focused on the development of novel small molecule therapeutics for oncology and immunology. The company's primary research centers on the discovery of oral PD-L1 inhibitors designed to provide a more accessible and manageable alternative to traditional injectable monoclonal antibodies. By targeting the PD-1/PD-L1 checkpoint pathway with small molecules, Mouri Pharma aims to enhance the efficacy of cancer immunotherapy while reducing the burden of administration. The company is currently advancing its lead candidates through pre-clinical validation with the goal of entering human clinical trials.